Olanzapine/fluoxetine: A review of its use in patients with treatment-resistant major depressive disorder

CNS Drugs

Volumn 24, Issue 3, 2010, Pages 245-262

  Croxtall, Jamie D ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CIPROFLOXACIN; CLOZAPINE; DIAZEPAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; RIFAMPICIN; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AKATHISIA; ANXIETY; AREA UNDER THE CURVE; ATTENTION DISTURBANCE; BIPOLAR DISORDER; BRADYCARDIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERSOMNIA; INCREASED APPETITE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERIPHERAL EDEMA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; REVIEW; RHINITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYNCOPE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREMOR; WEIGHT GAIN; XEROSTOMIA;

BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 76949088866     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11203830-000000000-00000     Document Type: Review

References (41)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder: second edition [online]. Available from URL: http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx? file=MDD2e-Inactivated-04-16-09 [Accessed 2009 Jul 30]
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comor-bidity Survey. Arch Gen Psychiatry 1994 Jan; 51 (1): 8-19
4. WHO. Global burden of unipolar depressive disorders in the year 2000 [online]. Available from URL: http://www.who. int/healthinfo/statistics/bod- depression.pdf [Accessed 2009 Sep 14]
5. Debattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009; 23 (5): 369-377
6. Rush A, Trivedi M, Wisniewski S, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163 (11): 1905-1917
7. Little A. Treatment-resistant depression. Am Fam Physician 2009; 80 (2): 167-172
8. Dodd S, Berk M. Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Rev Neurother 2008 Sep; 8 (9): 1299-1306
9. Tierney II J. Treatment-resistant depression: managed care considerations. J Manag Care Pharm 2007; 13 (6 Suppl. S-a): S2-7
10. Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 2002 Feb; 63 (2): 95-103
11. Deeks ED, Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. Drugs 2008; 68 (8): 1115-1137
12. Eli Lilly and Company. Symbyax® (olanzapine and fluox-etine hydrochloride) capsule for oral use: US prescribing information [online]. Available from URL: http://pi.lilly.com/us/symbyax-pi.pdf [Accessed 2009 Sep 3]
13. Bhana N, Perry C. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs 2001; 15 (11): 871-904 (Pubitemid 33135207)
14. Cheer S, Goa K. Fluoxetine: a review of its therapeutic po-tential in the treatment of depression associated with physical illness. Drugs 2001; 61 (1): 81-110
15. Bobo W, Shelton R. Fluoxetine and olanzapine combina-tion therapy in treatment resistant depression. Exp Opin Pharmacother 2009; 10 (13): 2145-2159
16. Koch S, Perry KW, Bymaster FP. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004 Feb; 46 (2): 232-242
17. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000 Sep; 23 (3): 250-262
18. Maragnoli ME, Fumagalli F, Gennarelli M, et al. Fluox-etine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 2004 Jun 1; 55 (11): 1095-1102
19. Seager MA, Huff KD, Barth VN, et al. Fluoxetine admin-istration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004 Jun 1; 55 (11): 1103-1109
20. Ordway G, Szebeni K. Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus. Int J Neuropyscho-pharmacol 2004; 7 (3): 321-327
21. Nestler EJ, McMahon A, Sabban EL, et al. Chronic anti-depressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci USA 1990 Oct; 87 (19): 7522-7526 (Pubitemid 20341748)
22. Kodama M, Fujioka T, Duman R. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004; 56 (8): 570-580
23. Kassahun K, Mattuiz E, Nyhart E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997; 25 (1): 81-93
24. Gossen D, de Suray JM, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4 (2): E11
25. Altamura A, Moro A, Percudani M. Clinical pharmacokine-tics of fluoxetine. Clin Pharmacokinet 1994; 26 (3): 201-214
26. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37 (3): 177-193
27. Harvey A, Preskorn S. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001; 21 (2): 161-166
28. Schenker S, Bergstrom RF, Wolen RL, et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988; 44 (3): 353-359
29. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004; 37 (2): 63-68
30. Shelton R, Tollefson G, Tohen M, et al. A novel augmen-tation strategy for treating resistant major depression. Am J Psychiatry 2001; 158 (1): 131-134
31. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005 Oct; 66 (10): 1289-1297
32. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007 Feb; 68 (2): 224-236
33. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23 (6): 364-372
34. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009 Mar; 70 (3): 387-396
35. Corya SA, Andersen SW, Detke HC, et al. Long-term anti-depressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003 Nov; 64 (11): 1349-1356
36. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005 Nov; 66 (11): 1468-1476
37. Melkersson K, Dahl ML. Adverse metabolic effects asso-ciated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64 (7): 701-723
38. Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression: systematic review. Br J Psychiatry 2002 Oct; 181: 284-294
39. Ackerman S, Nolan L. Bodyweight gain induced by psy-chotropic drugs: incidence, mechanisms and management. CNS Drugs 1998; 9 (2): 135-151
40. Dodd S, Berk M. Olanzapine plus fluoxetine reduce de-pressive symptoms faster than either drug alone in people with treatment resistant depression. Evid Based Ment Health 2006 May; 9 (2): 42
41. Greenberg P, Corey-Lisle P, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004; 22 (6): 363-373